N6-Cyclohexyladenosine

N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC50 = 8.2 nM) . N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[36396-99-3]

Product Name Alternative

CHA

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adenosine Receptor; Akt; Epigenetic Reader Domain; PI3K

Type

Reference compound

Related Pathways

Epigenetics; GPCR/G Protein; PI3K/Akt/mTOR

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/N6-Cyclohexyladenosine.html

Purity

99.98

Solubility

DMSO : ≥ 100 mg/mL

Smiles

OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3NC4CCCCC4)O1)O)O

Molecular Formula

C16H23N5O4

Molecular Weight

349.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Asghari AA, et al. Adenosine A1 receptor agonist, N6-cyclohexyladenosine, protects myelin and induces remyelination in an experimental model of rat optic chiasm demyelination; electrophysiological and histopathological studies. J Neurol Sci. 2013 Feb 15;325 (1-2) :22-28.|[2]Blanco-Centurion C, et al. Adenosine and sleep homeostasis in the Basal forebrain. J Neurosci. 2006 Aug 2;26 (31) :8092-100.|[3]Nikodijević O, et al. Characterization of the locomotor depression produced by an A2-selective adenosine agonist. FEBS Lett. 1990 Feb 12;261 (1) :67-70.|[4]Nakashima J, et al. Increased erythropoietin secretion in human hepatoma cells by N6-cyclohexyladenosine. Am J Physiol. 1991 Sep;261 (3 Pt 1) :C455-60.|[5]Churchill PC, et al. Renin secretory effects of N6-cyclohexyladenosine: effects of dietary sodium. Am J Physiol. 1987 May;252 (5 Pt 2) :F872-6. |[6]Rabie MA, et al. Adenosine A1 receptor agonist, N6-cyclohexyladenosine, attenuates Huntington's disease via stimulation of TrKB/PI3K/Akt/CREB/BDNF pathway in 3-nitropropionic acid rat model. Chem Biol Interact. 2023 Jan 5;369:110288.|[7]Liddle LJ, et al. An Assessment of Physical and N6-Cyclohexyladenosine-Induced Hypothermia in Rodent Distal Focal Ischemic Stroke. Ther Hypothermia Temp Manag. 2024 Mar;14 (1) :36-45.